Bleeding, Complications, Glucagon-like Peptide-1, STEMI - ST Elevation Myocardial Infarction
Conditions
Brief summary
Glucagon-like peptide-1 (GLP-1), produced mainly in enteroendocrine cells, participates in energy homeostasis and glucose metabolism by regulating islet hormone secretion, gastrointestinal motility, and food intake, making GLP-1 agonist a treatment for diabetes and obesity. Pre-clinical and clinical studies have demonstrated that GLP-1 also has cardio-protection effects. GLP-1 agonists is able to improve markers of cardiac function, reduce myocardial infarct size and post-myocardial infarction remodeling in experimental myocardial infarction. And GLP-1 infusion improved left ventricular function and increases myocardial salvage in patients with acute myocardial infarction (AMI). The investigators' previous study found that GLP-1 analogues attenuated ischemia-reperfusion induced apoptosis of stem- and myocardial microvascular endothelial cells, and liraglutide (a GLP-1 analog) usage during hospital stay can prevent no-reflow and improve heart function in AMI. Therefore, the investigators carried out a cohort study to evaluate the association between plasma GLP-1 and in-hospital complications in patients with ST-segment elevation myocardial infarction.
Interventions
None listed
Sponsors
Chinese PLA General Hospital
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* a diagnosis of STEMI and needed PCI
Exclusion criteria
* patients with cancer patients who used DPP4 inhibitor patients who used GLP1 analogue
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| in-hospital complications | Time Frame: up to 2 week after PCI (until discharge) | defined as acute heart failure, atrial fibrillation, chest pain or re-acute myocardial infarction, complete atrioventricular block, cerebrovascular disease, ventricular fibrillation or ventricular tachycardia |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| in-hospital major adverse cardiac or cerebrovascular events | Time Frame: up to 2 week after PCI (until discharge)] | the composite of death, nonfatal MI, or stroke |
| in-hospital major bleeding | Time Frame: up to 2 week after PCI (until discharge) | defined as absolute hemoglobin drop (baseline to nadir)≥4g/dl, intracranial hemorrhage, retroperitoneal hemorrhage, use of red blood cell transfusion in patients with a baseline hemoglobin ≥9.0 g/dl, and use of red blood cell transfusion among patients with a baseline hemoglobin \<9.0 g/dl and a witnessed bleeding event |
Outcome results
None listed